Wildcat Capital Management, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Wildcat Capital Management, LLC disclosed 8 US equity positions worth $252.7m in its Q4 2024 13F filing. The largest position was ULCC at 79.0% of the reported book, followed by RLX and ALLO. Against the Q3 2024 filing, it opened 3 new positions, added to 0 and reduced 0 among the top 8 holdings.
What did Wildcat Capital Management, LLC own in Q4 2024? Top 8 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ULCC FRONTIER GROUP HLDGS INC | Industrials | 79.0% | $199.5m | 28,061,351 | 0% | held |
| 2 | RLX RLX TECHNOLOGY INC | Consumer Defensive | 15.4% | $39.0m | 18,046,195 | 0% | held |
| 3 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 2.5% | $6.2m | 2,920,787 | 0% | held |
| 4 | URGN UROGEN PHARMA LTD | Healthcare | 2.1% | $5.3m | 495,606 | 0% | held |
| 5 | KRON1USD KRONOS BIO INC | 0.5% | $1.2m | 1,297,959 | 0% | held | |
| 6 | GTLB GITLAB INC | Technology | 0.3% | $642.3k | 11,399 | – | new |
| 7 | PCOR PROCORE TECHNOLOGIES INC | Technology | 0.2% | $606.6k | 8,095 | – | new |
| 8 | SILEXION THERAPEUTICS CORP | 0.1% | $228.0k | 113,428 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.